The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer.
Stephen V. Liu
No relevant relationships to disclose
Andrew V Schally
No relevant relationships to disclose
Tanya B. Dorff
No relevant relationships to disclose
Denice D. Tsao-Wei
No relevant relationships to disclose
Susan G. Groshen
No relevant relationships to disclose
Shigang Xiong
No relevant relationships to disclose
Debra Hawes
No relevant relationships to disclose
David I. Quinn
No relevant relationships to disclose
Yu-Chong Tai
No relevant relationships to disclose
Norman L. Block
Stock Ownership - Aeterna Zentaris
Juergen Engel
Employment or Leadership Position - Aeterna Zentaris
Stock Ownership - Aeterna Zentaris
Other Remuneration - Aeterna Zentaris
Jacek K. Pinski
No relevant relationships to disclose